Literature DB >> 6983568

Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis.

C Bolton, J F Borel, M L Cuzner, A N Davison, A M Turner.   

Abstract

Cyclosporin A (CsA), an immunosuppressant which acts selectively on antigen-responding T cells, was tried in the treatment of experimental allergic encephalomyelitis (EAE). The drug was highly effective in preventing the appearance of clinical and pathological signs of EAE in rats, guinea pigs and monkeys. Treatment of the established disease also reduced the incidence and severity of symptoms, and significantly reduced the number of inflammatory lesions in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6983568     DOI: 10.1016/0022-510x(82)90138-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Randomised double blind controlled trial of cyclosporin in multiple sclerosis.

Authors:  P Rudge; J C Koetsier; J Mertin; J O Mispelblom Beyer; H K Van Walbeek; R Clifford Jones; J Harrison; K Robinson; B Mellein; T Poole
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats.

Authors:  L Massacesi; E Castigli; M Vergelli; J Olivotto; A L Abbamondi; F Sarlo; L Amaducci
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

4.  Cyclosporin A and anti-glomerular basement membrane antibody glomerulonephritis in rats.

Authors:  A Wood; D Adu; R J Birtwistle; D B Brewer; J Michael
Journal:  Br J Exp Pathol       Date:  1988-04

5.  SLAT/Def6 plays a critical role in the development of Th17 cell-mediated experimental autoimmune encephalomyelitis.

Authors:  Ann J Canonigo-Balancio; Camille Fos; Thomas Prod'homme; Stéphane Bécart; Amnon Altman
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

6.  Prolongation of life in female NZB/NZW (F1) hybrid mice by cyclosporin A.

Authors:  M G Jones; G Harris
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

7.  Effects of cyclosporin A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis patients.

Authors:  V L Calder; A S Bellamy; S Owen; C Lewis; P Rudge; A N Davison; M Feldmann
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

8.  In vivo and in vitro models of demyelinating diseases. XXIV. The infectious process in cyclosporin A treated Wistar Lewis rats inoculated with JHM virus.

Authors:  M J Zimmer; S Dales
Journal:  Microb Pathog       Date:  1989-01       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.